In addition, Soiffer et al. provided the first hint that CD6 might be involved in the pathogenies of GVHD [81]; their studies showed that depleting CD6+ cells with an anti-CD6 IgM monoclonal antibody (anti-T12) prior to hematopoietic transplantation reduced the incidence of acute and chronic GVHD and obviated the need to administer immune suppressive medications. Here, CD6 is linked to graft versus host disease.